Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

It has been about a month since the last earnings report for Catalyst Pharmaceutical (CPRX). Shares have added about 11.4% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Neurocrine Biosciences (NBIX). But which of these two stocks is more ...

Below, we take a look at Catalyst Pharmaceutical (CPRX), a company that currently holds a Momentum Style Score of A. We also talk about price change and earnings estimate revisions, two of the ...

This was the stock's second consecutive day of gains.

CPRX sits at a Zacks Rank #2 (Buy), holds a Growth Style Score of B, and has a VGM Score of A. Earnings and sales are forecasted to increase 1.8% and 13.9% year-over-year, respectively. Four analysts ...

Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Neurocrine Biosciences (NBIX). But which of these two stocks is more ...